The National Institute for Health and Care Excellence (NICE) has issued recommendations for the use of Elacestrant in treating oestrogen receptor-positive (ER+), HER2-negative advanced breast cancer with an ESR1 mutation. This guidance offers a significant development for patients whose cancer has progressed following endocrine therapy plus a CDK4 and 6 inhibitor.
Elacestrant: a new option for ESR1-mutated breast cancer
Elacestrant is a selective and orally active estrogen receptor-α (ERα) antagonist and degrader, approved for patients with ER+, HER2-negative breast cancer that carries an ESR1 mutation. This mutation is known to drive resistance to standard endocrine therapies, limiting treatment options. NICE recommends Elacestrant for patients who have previously undergone at least one endocrine treatment combined with a CDK 4 and 6 inhibitor.
Why ESR1 mutation testing matters
Identifying the presence of an ESR1 mutation is critical to determining if Elacestrant is an appropriate treatment option. The AmoyDx ESR1 panel is a powerful solution for detecting ESR1 mutations with high sensitivity and precision.
Benefits of the AmoyDx ESR1 panel
- High Sensitivity: Detects low-frequency ESR1 mutations, crucial for identifying patients who may benefit from Elacestrant.
- Fast Turnaround: Provides rapid results, enabling timely treatment decisions.
- Proven Performance: The AmoyDx ESR1 panel is designed to deliver reliable and reproducible results in clinical testing environments.
By integrating the AmoyDx ESR1 panel into diagnostic workflows, clinicians can confidently identify patients who may benefit from Elacestrant, improving treatment outcomes and offering new hope for those with advanced breast cancer.
This content was adapted from the original NICE recommendation announcement.